Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Björn Dahlöf

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Devices

Electrocardiography

Concepts & Ideas

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
62
Kjeldsen, Sverre
62
Nieminen, Markku
61
Devereux, Richard
54
Wachtell, Kristian
43
Lindholm, Lars
37
Ibsen, Hans
37
Julius, Stevo
34
de Faire, Ulf
34
Wedel, Hans
32
Gerdts, Eva
29
Okin, Peter
27
Papademetriou, Vasilios
23
Oparil, Suzanne
22
Omvik, Per
22
Lederballe-Pedersen, Ole

Sign-in to see all Coauthors

Publications

TOP 3
de Simone G; Okin P M; Gerdts E; Olsen M H; Wachtell K; Hille D A; Dahlöf B; Kjeldsen S E; Devereux R B
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study.
Chinali Marcello; Aurigemma Gerard P; de Simone Giovanni; Mishra Rakesh K; Gerdts Eva; Wachtell Kristian; Boman Kurt; Dahlöf Björn; Devereux Richard B
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).
Poulter Neil R; Dobson Joanna E; Sever Peter S; Dahlöf Björn; Wedel Hans; Campbell Norm R C;
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Björn Dahlöf (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: de Simone G; Okin P M; Gerdts E; Olsen M H; Wachtell K; Hille D A; Dahlöf B; Kjeldsen S E; Devereux R B
Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2009;19(9):634-40.
2009: Chinali Marcello; Aurigemma Gerard P; de Simone Giovanni; Mishra Rakesh K; Gerdts Eva; Wachtell Kristian; Boman Kurt; Dahlöf Björn; Devereux Richard B
Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy).
The American journal of cardiology 2009;104(8):1098-104.
2009: Poulter Neil R; Dobson Joanna E; Sever Peter S; Dahlöf Björn; Wedel Hans; Campbell Norm R C;
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Journal of the American College of Cardiology 2009;54(13):1154-61.
2009: Boman Kurt; Gerdts Eva; Wachtell Kristian; Dahlöf Björn; Nieminen Markku S; Olofsson Mona; Papademetriou Vasilios; Devereux Richard B
Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2009;16(2):242-8.
2009: Okin Peter M; Oikarinen Lasse; Viitasalo Matti; Toivonen Lauri; Kjeldsen Sverre E; Nieminen Markku S; Edelman Jonathan M; Dahlöf Björn; Devereux Richard B;
Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Circulation 2009;119(14):1883-91.
2009: Olsen Michael Hecht; Wachtell Kristian; Beevers Gareth; Dahlöf Björn; de Simone Giovanni; Devereux Richard B; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kjeldsen Sverre E; Lederballe-Pedersen Ole; Lindholm Lars H; Lyle Paulette A; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2009;27(3):567-74.
2009: Dahlöf B
Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
Journal of human hypertension 2009;23(2):77-85.
2008: Okin Peter M; Wachtell Kristian; Kjeldsen Sverre E; Julius Stevo; Lindholm Lars H; Dahlöf Björn; Hille Darcy A; Nieminen Markku S; Edelman Jonathan M; Devereux Richard B
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Circulation. Arrhythmia and electrophysiology 2008;1(5):337-43.
2008: Jamerson Kenneth; Weber Michael A; Bakris George L; Dahlöf Björn; Pitt Bertram; Shi Victor; Hester Allen; Gupte Jitendra; Gatlin Marjorie; Velazquez Eric J;
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
The New England journal of medicine 2008;359(23):2417-28.
2008: Kaschina Elena; Grzesiak Aleksandra; Li Jun; Foryst-Ludwig Anna; Timm Melanie; Rompe Franziska; Sommerfeld Manuela; Kemnitz U Rudolf; Curato Caterina; Namsolleck Pawel; Tschöpe Carsten; Hallberg Anders; Alterman Mathias; Hucko Thomas; Paetsch Ingo; Dietrich Thore; Schnackenburg Bernhard; Graf Kristof; Dahlöf Björn; Kintscher Ulrich; Unger Thomas; Steckelings U Muscha
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
Circulation 2008;118(24):2523-32.
2008: Ostergren Jan; Poulter Neil R; Sever Peter S; Dahlöf Björn; Wedel Hans; Beevers Gareth; Caulfield Mark; Collins Rory; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin;
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Journal of hypertension 2008;26(11):2103-11.
2008: Gerdts Eva; Cramariuc Dana; de Simone Giovanni; Wachtell Kristian; Dahlöf Björn; Devereux Richard B
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 2008;9(6):809-15.
2008: Ritz Eberhard; Dahlöf Björn
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Nature clinical practice. Cardiovascular medicine 2008;5 Suppl 1():S1-2.
2008: Chapman Neil; Chang Choon Lan; Dahlöf Björn; Sever Peter S; Wedel Hans; Poulter Neil R;
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Circulation 2008;118(1):42-8.
2008: Chinali Marcello; de Simone Giovanni; Wachtell Kristian; Gerdts Eva; Gardin Julius M; Boman Kurt; Nieminen Markku S; Papademetriou Vasilios; Dahlöf Björn; Devereux Richard B
Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2008;26(7):1472-6.
2008: Okin Peter M; Gerdts Eva; Kjeldsen Sverre E; Julius Stevo; Edelman Jonathan M; Dahlöf Björn; Devereux Richard B;
Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
Hypertension 2008;52(1):100-6.
2008: Li Zhibin; Dahlöf Björn; Okin Peter M; Kjeldsen Sverre E; Wachtell Kristian; Ibsen Hans; Nieminen Markku S; Jern Sverker; Devereux Richard B
Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Journal of hypertension 2008;26(6):1244-9.
2008: Palmieri Vittorio; Bella Jonathan N; Gerdts Eva; Wachtell Kristian; Papademetriou Vasilios; Nieminen Markku S; Dahlöf Björn; Devereux Richard B
Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
American journal of hypertension 2008;21(6):701-7.
2008: Cicala Silvana; de Simone Giovanni; Wachtell Kristian; Gerdts Eva; Boman Kurt; Nieminen Markku S; Dahlöf Björn; Devereux Richard B
Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2008;26(4):806-12.
2008: Os Ingrid; Franco Veronica; Kjeldsen Sverre E; Manhem Karin; Devereux Richard B; Gerdts Eva; Hille Darcy A; Lyle Paulette A; Okin Peter M; Dahlöf Björn; Oparil Suzanne
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Hypertension 2008;51(4):1103-8.
2008: Okin Peter M; Wachtell Kristian; Devereux Richard B; Nieminen Markku S; Oikarinen Lasse; Viitasalo Matti; Toivonen Lauri; Ibsen Hans; Olsen Michael H; Borch-Johnsen Knut; Lindholm Lars H; Kjeldsen Sverre E; Julius Stevo; Dahlöf Björn;
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
American journal of hypertension 2008;21(3):273-9.
2008: Kjeldsen Sverre E; Jamerson Kenneth A; Bakris George L; Pitt Bertram; Dahlöf Björn; Velazquez Eric J; Gupte Jitendra; Staikos Linda; Hua Tsushung A; Shi Victor; Hester Allen; Tuomilehto Jaakko; Ostergren Jan; Ibsen Hans; Weber Michael;
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Blood pressure 2008;17(1):7-17.
2007: Okin Peter M; Devereux Richard B; Harris Katherine E; Jern Sverker; Kjeldsen Sverre E; Lindholm Lars H; Dahlöf Björn;
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Hypertension 2007;50(5):984-90.
2007: Fossum E; Gleim G W; Kjeldsen S E; Kizer J R; Julius S; Devereux R B; Brady W E; Hille D A; Lyle P A; Dahlöf B
The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
Journal of internal medicine 2007;262(4):439-48.
2007: Okin Peter M; Devereux Richard B; Harris Katherine E; Jern Sverker; Kjeldsen Sverre E; Julius Stevo; Edelman Jonathan M; Dahlöf Björn;
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Annals of internal medicine 2007;147(5):311-9.
2007: Smebye Marianne L; Iversen Emil K; Høieggen Aud; Flaa Arnljot; Os Ingrid; Kjeldsen Sverre E; Olsen Michael Hecht; Chattopadhyay Arghya; Hille Darcy A; Lyle Paulette A; Devereux Richard B; Dahlöf Björn
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
The American journal of cardiology 2007;100(5):855-9.
2007: Dahlöf Björn
Prevention of stroke in patients with hypertension.
The American journal of cardiology 2007;100(3A):17J-24J.
2007: de Simone G; Olsen M H; Wachtell K; Hille D A; Dahlöf B; Ibsen H; Kjeldsen S E; Lyle P A; Devereux R B
Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
Journal of human hypertension 2007;21(8):625-32.
2007: Palmieri Vittorio; Okin Peter M; de Simone Giovanni; Bella Jonathan N; Wachtell Kristian; Gerdts Eva; Boman Kurt; Nieminen Markku S; Dahlöf Björn; Devereux Richard B
Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Journal of hypertension 2007;25(5):1079-85.
2007: Chapman Neil; Dobson Joanna; Wilson Sarah; Dahlöf Björn; Sever Peter S; Wedel Hans; Poulter Neil R;
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Hypertension 2007;49(4):839-45.
2007: Devereux Richard B; Dahlöf Björn
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Current medical research and opinion 2007;23(2):443-57.
2007: Devereux Richard B; de Faire Ulf; Fyhrquist Frej; Harris Katherine E; Ibsen Hans; Kjeldsen Sverre E; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Hille Darcy A; Dahlöf Björn
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Current medical research and opinion 2007;23(2):259-70.
2007: Jamerson Kenneth; Bakris George L; Dahlöf Björn; Pitt Bertram; Velazquez Eric; Gupte Jitendra; Lefkowitz Martin; Hester Allen; Shi Victor; Kjeldsen Sverre E; Cushman William; Papademetriou Vasilios; Weber Michael;
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Blood pressure 2007;16(2):80-6.
2007: Weber Michael A; Bakris George L; Dahlöf Björn; Pitt Bertram; Velazquez Eric; Gupte Jitendra; Lefkowitz Martin; Hester Allen; Shi Victor; Weir Matthew; Kjeldsen Sverre; Massie Barry; Nesbitt Shawna; Ofili Elizabeth; Jamerson Kenneth
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Blood pressure 2007;16(1):13-9.
2007: Dahlöf Björn; Devereux Richard B; Kjeldsen Sverre E; Lyle Paulette A; Zhang Zhongxin; Edelman Jonathan M
Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Blood pressure 2007;16(1):6-12.
2006: Sever Peter; Dahlöf Björn; Poulter Neil; Wedel Hans; Beevers Gareth; Caulfield Mark; Collins Rory; Kjeldsen Sverre; Kristinsson Arni; McInnes Gordon; Mehlsen Jesper; Nieminem Markku; O'Brien Eoin; Ostergren Jan;
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
European heart journal 2006;27(24):2982-8.
2006: Palmieri Vittorio; Okin Peter M; Bella Jonathan N; Wachtell Kristian; Oikarinen Lasse; Gerdts Eva; Boman Kurt; Nieminen Markku S; Dahlöf Björn; Devereux Richard B
Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2006;24(10):2079-84.
2006: Okin Peter M; Wachtell Kristian; Devereux Richard B; Harris Katherine E; Jern Sverker; Kjeldsen Sverre E; Julius Stevo; Lindholm Lars H; Nieminen Markku S; Edelman Jonathan M; Hille Darcy A; Dahlöf Björn
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
JAMA : the journal of the American Medical Association 2006;296(10):1242-8.
2006: Olsen M H; Wachtell K; Dahlöf B; Devereux R B; Ibsen H; Kjeldsen S E; Lindholm L H; Lyle P A; Nieminen M S
The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Journal of human hypertension 2006;20(6):460-4.
2006: Dahlöf Björn
Prospects for the prevention of stroke.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2006;24(2):S3-9.
2006: Haffner Steve M; Ruilope Luis; Dahlöf Björn; Abadie Eric; Kupfer Stuart; Zannad Faiez
Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
Journal of cardiovascular pharmacology 2006;47(3):469-75.
2006: Okin Peter M; Devereux Richard B; Gerdts Eva; Snapinn Steven M; Harris Katherine E; Jern Sverker; Kjeldsen Sverre E; Julius Stevo; Edelman Jonathan M; Lindholm Lars H; Dahlöf Björn;
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Circulation 2006;113(12):1588-96.
2006: Ibsen Hans; Olsen Michael H; Wachtell Kristian; Borch-Johnsen Knut; Lindholm Lars H; Mogensen Carl E; Dahlöf Björn; Snapinn Steven M; Wan Ying; Lyle Paulette A
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Diabetes care 2006;29(3):595-600.
2006: Okin Peter M; Devereux Richard B; Nieminen Markku S; Jern Sverker; Oikarinen Lasse; Viitasalo Matti; Toivonen Lauri; Kjeldsen Sverre E; Dahlöf Björn;
Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Circulation 2006;113(1):67-73.
2005: Carr Albert A; Kowey Peter R; Devereux Richard B; Brenner Barry M; Dahlöf Björn; Ibsen Hans; Lindholm Lars H; Lyle Paulette A; Snapinn Steven M; Zhang Zhongxin; Edelman Jonathan M; Shahinfar Shahnaz
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
The American journal of cardiology 2005;96(11):1530-6.
2005: Kjeldsen Sverre E; Lyle Paulette A; Tershakovec Andrew M; Devereux Richard B; Oparil Suzanne; Dahlöf Björn; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Wedel Hans
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Expert opinion on emerging drugs 2005;10(4):729-45.
2005: Dahlöf Björn; Gosse Philippe; Guéret Pascal; Dubourg Olivier; de Simone Giovanni; Schmieder Roland; Karpov Yuri; García-Puig Juan; Matos Lajos; De Leeuw Peter W; Degaute Jean-Paul; Magometschnigg Dieter;
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study.
Journal of hypertension 2005;23(11):2063-70.
2005: Dahlöf Björn; Degl' Innocenti Alessio; Elmfeldt Dag; Puig Juan Garcia; Gundersen Torstein; Hosie James; Januszewicz Wlodzimierz; Lindström Carl-Johan; Magometschnigg Dieter; Tanser Paul; Toutouzas Pavles; Waeber Bernhard; Wiklund Ingela
Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction.
American journal of hypertension 2005;18(10):1313-9.
2005: Poulter Neil R; Wedel Hans; Dahlöf Björn; Sever Peter S; Beevers D Gareth; Caulfield Mark; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin; Ostergren Jan; Pocock Stuart;
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Lancet 2005;366(9489):907-13.
2005: Dahlöf Björn; Sever Peter S; Poulter Neil R; Wedel Hans; Beevers D Gareth; Caulfield Mark; Collins Rory; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin; Ostergren Jan;
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Lancet 2005;366(9489):895-906.
2005: Fossum Eigil; Moan Andreas; Kjeldsen Sverre E; Devereux Richard B; Julius Stevo; Snapinn Steven M; Edelman Jonathan M; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Dahlöf Björn;
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;46(5):770-5.
2005: Sever Peter S; Poulter Neil R; Dahlöf Björn; Wedel Hans;
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
The American journal of cardiology 2005;96(5A):39F-44F.
2005: Jönsson Bengt; Carides George W; Burke Thomas A; Dasbach Erik J; Lindholm Lars H; Dahlöf Björn;
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Journal of hypertension 2005;23(7):1425-31.
2005: Dahlöf B
Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
Journal of human hypertension 2005;19 Suppl 1():S9-14.
2005: Sever Peter S; Poulter Neil R; Dahlöf Björn; Wedel Hans; Collins Rory; Beevers Gareth; Caulfield Mark; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin; Ostergren Jan
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Diabetes care 2005;28(5):1151-7.
2005: Dahlöf B; Ritz E
Introduction.
Acta diabetologica 2005;42 Suppl 1():S1-2.
2005: de Simone Giovanni; Wachtell Kristian; Palmieri Vittorio; Hille Darcy A; Beevers Gareth; Dahlöf Björn; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Julius Stevo; Kjeldsen Sverre E; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Devereux Richard B
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Circulation 2005;111(15):1924-31.
2005: Fyhrquist Frej; Dahlöf Björn; Devereux Richard B; Kjeldsen Sverre E; Julius Stevo; Beevers Gareth; de Faire Ulf; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Hille Darcy A; Lyle Paulette A; Edelman Jonathan M; Snapinn Steven M; Wedel Hans;
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Hypertension 2005;45(4):580-5.
2005: Kjeldsen Sverre E; Lyle Paulette A; Kizer Jorge R; Dahlöf Björn; Devereux Richard B; Julius Stevo; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Snapinn Steven M; Harris Katherine E; Wedel Hans;
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(3):152-8.
2005: Wachtell Kristian; Lehto Mika; Gerdts Eva; Olsen Michael H; Hornestam Björn; Dahlöf Björn; Ibsen Hans; Julius Stevo; Kjeldsen Sverre E; Lindholm Lars H; Nieminen Markku S; Devereux Richard B
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;45(5):712-9.
2005: Wachtell Kristian; Hornestam Björn; Lehto Mika; Slotwiner David J; Gerdts Eva; Olsen Michael H; Aurup Peter; Dahlöf Björn; Ibsen Hans; Julius Stevo; Kjeldsen Sverre E; Lindholm Lars H; Nieminen Markku S; Rokkedal Jens; Devereux Richard B
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;45(5):705-11.
2005: Ibsen Hans; Olsen Michael H; Wachtell Kristian; Borch-Johnsen Knut; Lindholm Lars H; Mogensen Carl Erik; Dahlöf Björn; Devereux Richard B; de Faire Ulf; Fyhrquist Frej; Julius Stevo; Kjeldsen Sverre E; Lederballe-Pedersen Ole; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wan Ying
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Hypertension 2005;45(2):198-202.
2005: Boman Kurt; Olofsson Mona; Dahlöf Björn; Gerdts Eva; Nieminen Markku S; Papademetriou Vasilios; Wachtell Kristian; Devereux Richard B
Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study).
The American journal of cardiology 2005;95(2):280-3.
2005: Kizer Jorge R; Dahlöf Björn; Kjeldsen Sverre E; Julius Stevo; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Wachtell Kristian; Edelman Jonathan M; Snapinn Steven M; Harris Katherine E; Devereux Richard B
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Hypertension 2005;45(1):46-52.
2005: Linjer Erland; Hedner Thomas; Jönsson Bengt; Ekbom Tord; Lindholm Lars H; Dahlöf Björn; de Faire Ulf; Scherstén Bengt;
Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Blood pressure 2005;14(2):107-13.
2004: Devereux Richard B; Wachtell Kristian; Gerdts Eva; Boman Kurt; Nieminen Markku S; Papademetriou Vasilios; Rokkedal Jens; Harris Katherine; Aurup Peter; Dahlöf Björn
Prognostic significance of left ventricular mass change during treatment of hypertension.
JAMA : the journal of the American Medical Association 2004;292(19):2350-6.
2004: Okin Peter M; Devereux Richard B; Jern Sverker; Kjeldsen Sverre E; Julius Stevo; Nieminen Markku S; Snapinn Steven; Harris Katherine E; Aurup Peter; Edelman Jonathan M; Wedel Hans; Lindholm Lars H; Dahlöf Björn;
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
JAMA : the journal of the American Medical Association 2004;292(19):2343-9.
2004: Ibsen Hans; Wachtell Kristian; Olsen Michael H; Borch-Johnsen Knut; Lindholm Lars H; Mogensen Carl Erik; Dahlöf Björn
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.
Kidney international. Supplement 2004;(92):S56-8.
2004: Olsen Michael H; Wachtell Kristian; Bella Jonathan N; Liu Jennifer E; Boman Kurt; Gerdts Eva; Papademetriou Vasilios; Nieminen Markku S; Rokkedal Jens; Dahlöf Björn; Devereux Richard B
Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy).
The American journal of cardiology 2004;94(8):1076-80.
2004: Wachtell Kristian; Papademetriou Vasilios; Smith Gunnar; Gerdts Eva; Dahlöf Björn; Engblom Erik; Aurigemma Gerard P; Bella Jonathan N; Ibsen Hans; Rokkedal Jens; Devereux Richard B
Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
American heart journal 2004;148(3):538-44.
2004: Jamerson Kenneth A; Bakris George L; Wun Chuan-Chuan; Dahlöf Björn; Lefkowitz Martin; Manfreda Sheryl; Pitt Bertram; Velazquez Eric J; Weber Michael A
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.
American journal of hypertension 2004;17(9):793-801.
2004: Devereux Richard B; Dahlöf Björn; Gerdts Eva; Boman Kurt; Nieminen Markku S; Papademetriou Vasilios; Rokkedal Jens; Harris Katherine E; Edelman Jonathan M; Wachtell Kristian
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Circulation 2004;110(11):1456-62.
2004: Ibsen Hans; Wachtell Kristian; Olsen Michael H; Borch-Johnsen Knut; Lindholm Lars H; Mogensen Carl Erik; Dahlöf Björn; Devereux Richard B; de Faire Ulf; Fyhrquist Frej; Julius Stevo; Kjeldsen Sverre E; Lederballe-Pedersen Ole; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wan Ying;
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Journal of hypertension 2004;22(9):1805-11.
2004: Ciulla Michele M; Paliotti Roberta; Esposito Arturo; Dìez Javier; López Begoña; Dahlöf Björn; Nicholls M Gary; Smith Ronald D; Gilles Leen; Magrini Fabio; Zanchetti Alberto
Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.
Circulation 2004;110(5):552-7.
2004: Okin Peter M; Devereux Richard B; Nieminen Markku S; Jern Sverker; Oikarinen Lasse; Viitasalo Matti; Toivonen Lauri; Kjeldsen Sverre E; Julius Stevo; Snapinn Steven; Dahlöf Björn;
Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.
Hypertension 2004;44(1):48-54.
2004: Reims H M; Kjeldsen S E; Brady W E; Dahlöf B; Devereux R B; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm L H; Nieminen M S; Omvik P; Oparil S; Wedel H
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):381-9.
2004: Li Z B; Wachtell K; Okin P M; Gerdts E; Liu J E; Nieminen M S; Jern S; Dahlöf B; Devereux R B
Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):397-402.
2004: Okin P M; Devereux R B; Liu J E; Oikarinen L; Jern S; Kjeldsen S E; Julius S; Wachtell K; Nieminen M S; Dahlöf B
Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Journal of human hypertension 2004;18(6):403-9.
2004: Bella J N; Palmieri V; Wachtell K; Liu J E; Gerdts E; Nieminen M S; Koren M J; Zabalgoitia M; Wright J T; Dahlöf B; Devereux R B
Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Journal of human hypertension 2004;18(6):411-6.
2004: Dahlöf B; Burke T A; Krobot K; Carides G W; Edelman J M; Devereux R B; Diener H-C
Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Journal of human hypertension 2004;18(6):367-73.
2004: Palmieri V; Wachtell K; Bella J N; Gerdts E; Papademetriou V; Nieminen M S; Dahlöf B; Roman M J; Devereux R B
Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):423-30.
2004: Oikarinen Lasse; Nieminen Markku S; Viitasalo Matti; Toivonen Lauri; Jern Sverker; Dahlöf Björn; Devereux Richard B; Okin Peter M;
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Hypertension 2004;43(5):1029-34.
2004: Julius Stevo; Alderman Michael H; Beevers Gareth; Dahlöf Björn; Devereux Richard B; Douglas Janice G; Edelman Jonathan M; Harris Katherine E; Kjeldsen Sverre E; Nesbitt Shawna; Randall Otelio S; Wright Jackson T
Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study.
Journal of the American College of Cardiology 2004;43(6):1047-55.
2004: Høieggen Aud; Alderman Michael H; Kjeldsen Sverre E; Julius Stevo; Devereux Richard B; De Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Chen Cong; Dahlöf Björn;
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney international 2004;65(3):1041-9.
2004: Reims Henrik M; Oparil Suzanne; Kjeldsen Sverre E; Devereux Richard B; Julius Stevo; Brady William E; Fyhrquist Frej; Ibsen Hans; Lindholm Lars H; Omvik Per; Wedel Hans; Beevers Gareth; de Faire Ulf; Kristianson Krister; Lederballe-Pedersen Ole; Nieminen Markku S; Dahlöf Björn;
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Blood pressure 2004;13(6):376-84.
2004: Sever Peter S; Dahlöf Björn; Poulter Neil R; Wedel Hans; Beevers Gareth; Caulfield Mark; Collins Rory; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin; Ostergren Jan;
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Drugs 2004;64 Suppl 2():43-60.
2004: Ekbom Tord; Linjer Erland; Hedner Thomas; Lanke Jan; De Faire Ulf; Wester P-O; Dahlöf Björn; Scherstén Bengt
Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Blood pressure 2004;13(3):137-41.
2003: Wachtell Kristian; Ibsen Hans; Olsen Michael H; Borch-Johnsen Knut; Lindholm Lars H; Mogensen Carl Erik; Dahlöf Björn; Devereux Richard B; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Julius Stevo; Kjeldsen Sverre E; Kristianson Krister; Lederballe-Pedersen Ole; Nieminen Markku S; Okin Peter M; Omvik Per; Oparil Suzanne; Wedel Hans; Snapinn Steven M; Aurup Peter
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Annals of internal medicine 2003;139(11):901-6.
2003: Lindholm Lars H; Dahlöf Björn; Edelman Jonathan M; Ibsen Hans; Borch-Johnsen Knut; Olsen Michael Hecht; Snapinn Steven; Wachtell Kristian;
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Lancet 2003;362(9384):619-20.
2003: Devereux Richard B; Dahlöf Björn; Kjeldsen Sverre E; Julius Stevo; Aurup Peter; Beevers Gareth; Edelman Jonathan M; de Faire Ulf; Fyhrquist Frej; Helle Berg Sigrid; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Snapinn Steven; Wedel Hans;
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Annals of internal medicine 2003;139(3):169-77.
2003: Oikarinen Lasse; Nieminen Markku S; Toivonen Lauri; Viitasalo Matti; Wachtell Kristian; Papademetriou Vasilios; Jern Sverker; Dahlöf Björn; Devereux Richard B; Okin Peter M;
Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
American heart journal 2003;145(5):919-25.
2003: Sever Peter S; Dahlöf Björn; Poulter Neil R; Wedel Hans; Beevers Gareth; Caulfield Mark; Collins Rory; Kjeldsen Sverre E; Kristinsson Arni; McInnes Gordon T; Mehlsen Jesper; Nieminen Markku; O'Brien Eoin; Ostergren Jan;
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet 2003;361(9364):1149-58.
2003: Palmieri Vittorio; Bella Jonathan N; Roman Mary J; Gerdts Eva; Papademetriou Vasilios; Wachtell Kristian; Nieminen Markku S; Dahlöf Björn; Devereux Richard B
Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study.
Journal of hypertension 2003;21(4):781-7.
2003: Aurigemma Gerard P; Devereux Richard B; Wachtell Kristian; Palmieri Vittorio; Boman Kurt; Gerdts Eva; Nieminen Markku S; Papademetriou Vasilios; Dahlöf Bjorn
Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment.
American journal of hypertension 2003;16(3):180-6.
2003: Palmieri Vittorio; Okin Peter M; Bella Jonathan N; Gerdts Eva; Wachtell Kristian; Gardin Julius; Papademetriou Vasilios; Nieminen Markku S; Dahlöf Björn; Devereux Richard B;
Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Hypertension 2003;41(1):75-82.
2002: Wachtell Kristian; Dahlöf Björn; Rokkedal Jens; Papademetriou Vasilious; Nieminen Markku S; Smith Gunnar; Gerdts Eva; Boman Kurt; Bella Jonathan N; Devereux Richard B
Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
American heart journal 2002;144(6):1057-64.
2002: Zanchetti Alberto; Hansson Lennart; Dahlöf Björn; Julius Stevo; Ménard Joël; Warnold Ingrid; Wedel Hans;
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk.
Journal of hypertension 2002;20(11):2301-7.
2002: Kjeldsen Sverre E; Dahlöf Björn; Devereux Richard B; Julius Stevo; Aurup Peter; Edelman Jonathan; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristianson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Snapinn Steven; Wedel Hans;
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
JAMA : the journal of the American Medical Association 2002;288(12):1491-8.
2002: Gosse P; Dubourg O; Guéret P; De Simone G; Schmieder R; De Leeuw P W; Degaute J-P; García Puig J; Karpov Y; Magometschnigg D; Matos L; Amouyel P; Asmar R; Le Heuzey J-Y; Nieminen M; Dahlöf B
Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design.
Journal of human hypertension 2002;16(9):653-9.
2002: Lindholm Lars H; Ibsen Hans; Borch-Johnsen Knut; Olsen Michael Hecht; Wachtell Kristian; Dahlöf Björn; Devereux Richard B; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Julius Stevo; Kjeldsen Sverre E; Kristianson Krister; Lederballe-Pedersen Ole; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Aurup Peter; Edelman Jonathan M; Snapinn Steven;
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2002;20(9):1879-86.
2002: Okin Peter M; Wright Jackson T; Nieminen Markku S; Jern Sverker; Taylor Anne L; Phillips Robert; Papademetriou Vasilio; Clark Luther T; Ofili Elizabeth O; Randall Otelio S; Oikarinen Lasse; Viitasalo Matti; Toivonen Lauri; Julius Stevo; Dahlöf Björn; Devereux Richard B
Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2002;15(8):663-71.
2002: Devereux Richard B; Palmieri Vittorio; Liu Jennifer E; Wachtell Kristian; Bella Jonathan N; Boman Kurt; Gerdts Eva; Nieminen Markku S; Papademetriou Vasilios; Dahlöf Björn
Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Journal of hypertension 2002;20(7):1445-50.
2002: Wachtell Kristian; Palmieri Vittorio; Olsen Michael H; Gerdts Eva; Papademetriou Vasilios; Nieminen Markku S; Smith Gunnar; Dahlöf Björn; Aurigemma Gerard P; Devereux Richard B
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Circulation 2002;106(2):227-32.
2002: Kjeldsen Sverre E; Hedner Thomas; Syvertsen Jan Otto; Lund-Johansen Per; Hansson Lennart; Lanke Jan; Lindholm Lars H; De Faire Ulf; Dahlöf Björn; Karlberg Bengt E;
Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study.
Journal of hypertension 2002;20(6):1231-7.
2002: Lindholm Lars H; Ibsen Hans; Dahlöf Björn; Devereux Richard B; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Julius Stevo; Kjeldsen Sverre E; Kristiansson Krister; Lederballe-Pedersen Ole; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans; Aurup Peter; Edelman Jonathan; Snapinn Steven;
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):1004-10.
2002: Dahlöf Björn; Devereux Richard B; Kjeldsen Sverre E; Julius Stevo; Beevers Gareth; de Faire Ulf; Fyhrquist Frej; Ibsen Hans; Kristiansson Krister; Lederballe-Pedersen Ole; Lindholm Lars H; Nieminen Markku S; Omvik Per; Oparil Suzanne; Wedel Hans;
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):995-1003.
2002: Wachtell Kristian; Bella Jonathan N; Rokkedal Jens; Palmieri Vittorio; Papademetriou Vasilios; Dahlöf Björn; Aalto Tapio; Gerdts Eva; Devereux Richard B
Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Circulation 2002;105(9):1071-6.
2002: Wachtell Kristian; Olsen Michael H; Dahlöf Björn; Devereux Richard B; Kjeldsen Sverre E; Nieminen Markku S; Okin Peter M; Papademetriou Vasilios; Mogensen Carl E; Borch-Johnsen Knut; Ibsen Hans
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
Journal of hypertension 2002;20(3):405-12.
2002: Kostis John B; Cobbe Stuart; Johnston Colin; Ford Ian; Murphy Michael; Weber Michael A; Black Henry R; Plouin Pierre Francois; Levy Daniel; Mancia Guiseppe; Larochelle Pierre; Kolloch Rainer E; Alderman Michael; Ruilope Luis Miguel; Dahlöf Björn; Flack John M; Wolf Robert;
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
American journal of hypertension 2002;15(2 Pt 1):193-8.
2002: Wachtell Kristian; Palmieri Vittorio; Olsen Michael H; Bella Jonathan N; Aalto Tapio; Dahlöf Björn; Gerdts Eva; Wright Jackson T; Papademetriou Vasilios; Mogensen Carl E; Borch-Johnsen Knut; Ibsen Hans; Devereux Richard B
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
American heart journal 2002;143(2):319-26.
2002: Bella Jonathan N; Wachtell Kristian; Boman Kurt; Palmieri Vittorio; Papademetriou Vasilios; Gerdts Eva; Aalto Tapio; Olsen Michael H; Olofsson Mona; Dahlöf Björn; Roman Mary J; Devereux Richard B
Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study).
The American journal of cardiology 2002;89(3):337-41.
2001: Oikarinen L; Nieminen M S; Viitasalo M; Toivonen L; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux R B; Okin P M
Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction.
Journal of hypertension 2001;19(10):1883-91.
2001: Zabalgoitia M; Berning J; Koren M J; Støylen A; Nieminen M S; Dahlöf B; Devereux R B;
Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study).
The American journal of cardiology 2001;88(6):646-50.
2001: Sever P S; Dahlöf B; Poulter N R; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S E; McInnes G T; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Journal of human hypertension 2001;15 Suppl 1():S11-2.
2001: Lindholm L H; Anderson H; Ekbom T; Hansson L; Lanke J; Dahlöf B; de Faire U; Forsén K; Hedner T; Linjer E; Scherstén B; Wester P; Möller T
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial.
Lancet 2001;358(9281):539-44.
2001: Okin P M; Devereux R B; Jern S; Julius S; Kjeldsen S E; Dahlöf B
Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
American journal of hypertension 2001;14(8 Pt 1):775-82.
2001: Zanchetti A; Hansson L; Dahlöf B; Elmfeldt D; Kjeldsen S; Kolloch R; Larochelle P; McInnes G T; Mallion J M; Ruilope L; Wedel H
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.
Journal of hypertension 2001;19(6):1149-59.
2001: Sever P S; Dahlöf B; Poulter N R; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S E; McInnes G T; Mehlsen J; Nieminen M; O'Brien E; Ostergren J
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
Journal of hypertension 2001;19(6):1139-47.
2001: Palmieri V; Wachtell K; Gerdts E; Bella J N; Papademetriou V; Tuxen C; Nieminen M S; Dahlöf B; de Simone G; Devereux R B
Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
American heart journal 2001;141(5):784-91.
2001: Dahlöf B
Left ventricular hypertrophy and angiotensin II antagonists.
American journal of hypertension 2001;14(2):174-82.
2001: Bella J N; Wachtell K; Palmieri V; Liebson P R; Gerdts E; Ylitalo A; Koren M J; Pedersen O L; Rokkedal J; Dahlöf B; Roman M J; Devereux R B
Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
Journal of hypertension 2001;19(1):127-34.
2001: Wachtell K; Rokkedal J; Bella J N; Aalto T; Dahlöf B; Smith G; Roman M J; Ibsen H; Aurigemma G P; Devereux R B
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
The American journal of cardiology 2001;87(1):54-60.
2001: Devereux R B; Bella J; Boman K; Gerdts E; Nieminen M S; Rokkedal J; Papademetriou V; Wachtell K; Wright J; Paranicas M; Okin P M; Roman M J; Smith G; Dahlöf B
Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study.
Blood pressure 2001;10(2):74-82.
2000: Okin P M; Devereux R B; Jern S; Kjeldsen S E; Julius S; Dahlöf B
Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Hypertension 2000;36(5):766-73.
2000: Lindholm L H; Hansson L; Ekbom T; Dahlöf B; Lanke J; Linjer E; Scherstén B; Wester P O; Hedner T; de Faire U
Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.
Journal of hypertension 2000;18(11):1671-5.
2000: Kjeldsen S E; Dahlöf B; Devereux R B; Julius S; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm L H; Nieminen M S; Omvik P; Oparil S; Wedel H
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2000;13(8):899-906.
2000: Willenheimer R; Dahlöf B; Gordon A
Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?
Heart (British Cardiac Society) 2000;84(2):129-33.
2000: Hansson L; Hedner T; Lund-Johansen P; Kjeldsen S E; Lindholm L H; Syvertsen J O; Lanke J; de Faire U; Dahlöf B; Karlberg B E
Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.
Lancet 2000;356(9227):359-65.
2000: Wachtell K; Smith G; Gerdts E; Dahlöf B; Nieminen M S; Papademetriou V; Bella J N; Ibsen H; Rokkedal J; Devereux R B
Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
The American journal of cardiology 2000;85(4):466-72.
2000: Okin P M; Jern S; Devereux R B; Kjeldsen S E; Dahlöf B;
Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Hypertension 2000;35(1 Pt 1):13-8.
2000: Wachtell K; Bella J N; Liebson P R; Gerdts E; Dahlöf B; Aalto T; Roman M J; Papademetriou V; Ibsen H; Rokkedal J; Devereux R B
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study.
Hypertension 2000;35(1 Pt 1):6-12.
1999: Hansson L; Lindholm L H; Ekbom T; Dahlöf B; Lanke J; Scherstén B; Wester P O; Hedner T; de Faire U
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Lancet 1999;354(9192):1751-6.
1999: Palmieri V; Dahlöf B; DeQuattro V; Sharpe N; Bella J N; de Simone G; Paranicas M; Fishman D; Devereux R B
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement.
Journal of the American College of Cardiology 1999;34(5):1625-32.
1999: Waeber B; Detry J M; Dahlöf B; Puig J G; Gundersen T; Hosie J; Januszewicz W; Lindström C J; Magometschnigg D; Safar M; Tanser P; Toutouzas P
Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy?
American journal of hypertension 1999;12(9 Pt 1):915-20.
1999: Hansson L; Lindholm L H; Niskanen L; Lanke J; Hedner T; Niklason A; Luomanmäki K; Dahlöf B; de Faire U; Mörlin C; Karlberg B E; Wester P O; Björck J E
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Lancet 1999;353(9153):611-6.
1998: Dahlöf B; Devereux R B; Julius S; Kjeldsen S E; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm L H; Nieminen M S; Omvik P; Oparil S; Wedel H
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Hypertension 1998;32(6):989-97.
1998: Hansson L; Zanchetti A; Carruthers S G; Dahlöf B; Elmfeldt D; Julius S; Ménard J; Rahn K H; Wedel H; Westerling S
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Lancet 1998;351(9118):1755-62.
1998: Herlitz H; Dahlöf B; Jonsson O; Friberg P
Relationship between salt and blood pressure in hypertensive patients on chronic ACE-inhibition.
Blood pressure 1998;7(1):47-52.
1997: Hansson L; Hedner T; Lindholm L; Niklason A; Luomanmäki K; Niskanen L; Lanke J; Dahlöf B; de Faire U; Mörlin C; Karlberg B E; Wester P O; Björck J E
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status.
Blood pressure 1997;6(6):365-7.
1997: Dahlöf B; Lindholm L H; Carney S; Pentikäinen P J; Ostergren J
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.
Journal of hypertension 1997;15(11):1327-35.
1997: Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm L H; Nieminen M S; Omvik P; Oparil S; Wedel H
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
American journal of hypertension 1997;10(7 Pt 1):705-13.
1996: Lindholm L H; Hansson L; Dahlöf B; Ekbom T; Hedner T; De Faire U; Scherstén B; Wester P O
The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report.
Blood pressure 1996;5(5):300-4.
1995: Dahlöf B
Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
Journal of human hypertension 1995;9 Suppl 5():S37-44.
1995: Dahlöf B; Keller S E; Makris L; Goldberg A I; Sweet C S; Lim N Y
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
American journal of hypertension 1995;8(6):578-83.
1994: Ekbom T; Lindholm L H; Odén A; Dahlöf B; Hansson L; Wester P O; Scherstén B
A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people.
Journal of internal medicine 1994;235(6):581-8.
1994: Dahlöf B
Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
Blood pressure. Supplement 1994;2():35-40.
1993: Dahlöf B; Hansson L; Lindholm L H; Scherstén B; Ekbom T; Wester P O
Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1993;15(6):925-39.
1993: Johannesson M; Dahlöf B; Lindholm L H; Ekbom T; Hansson L; Odén A; Scherstén B; Wester P O; Jönsson B
The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension).
Journal of internal medicine 1993;234(3):317-23.
1993: Dahlöf B; Hansson L
The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide.
Journal of internal medicine 1993;234(3):271-9.
1993: Dahlöf B; Hansson L; Lindholm L H; Scherstén B; Wester P O; Ekbom T; Hedner T; de Faire U
STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension.
Blood pressure 1993;2(2):136-41.
1993: Dahlöf B
The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1993;11(3):S29-35.
1993: Dahlöf B; Jönsson L; Borgholst O; Ekblad G; Engstrand C; Grundestam I; Lindh A
Improved antihypertensive efficacy of the felodipine-metoprolol extended-release tablet compared with each drug alone.
Blood pressure. Supplement 1993;1():37-45.
1993: Dahlöf B; Hosie J
Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group.
Blood pressure. Supplement 1993;1():22-9.
1992: Ekbom T; Dahlöf B; Hansson L; Lindholm L H; Scherstén B; Wester P O
Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study.
Journal of hypertension 1992;10(12):1525-30.
1992: Dahlöf B; Hansson L
Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide.
Journal of hypertension 1992;10(12):1513-24.
1992: Dahlöf B; Herlitz H; Aurell M; Hansson L
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system.
American journal of hypertension 1992;5(12 Pt 1):900-11.
1992: Ekbom T; Dahlöf B; Hansson L; Lindholm L H; Odén A; Scherstén B; Wester P O
The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure--insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).
Blood pressure 1992;1(3):168-72.
1992: Hansson L; Hedner T; Dahlöf B
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point.
Blood pressure 1992;1(2):113-9.
1992: Dahlöf B; Stenkula S; Hansson L
Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment.
Blood pressure 1992;1(1):35-44.
1992: Dahlöf B; Pennert K; Hansson L
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.
American journal of hypertension 1992;5(2):95-110.
1992: Dahlöf B; Pennert K; Hansson L
Regression of left ventricular hypertrophy--a meta-analysis.
Clinical and experimental hypertension. Part A, Theory and practice 1992;14(1-2):173-80.
1992: Dahlöf B
Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy.
Blood pressure. Supplement 1992;6():1-75.
1991: de Faire U; Dahlöf B; Enström I; Hansson L; Hedner T; Lanke J; Lindholm L; Samuelsson O; Schwan A; Thulin T
[Ambulatory blood pressure measurement--guidelines for registration and data processing]
Läkartidningen 1991;88(50):4352-5.
1991: Dahlöf B; Ekbom T; Hansson L; Lindholm L; Scherstén B; Wester P O
[Antihypertensive treatment reduces the risk of stroke even in elderly hypertensive patients]
Läkartidningen 1991;88(49):4229-30.
1991: Dahlöf B; Lindholm L H; Hansson L; Scherstén B; Ekbom T; Wester P O
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Lancet 1991;338(8778):1281-5.
1991: Hansson L; Dahlöf B; Ekbom T; Lindholm L; Scherstén B; Wester P O
Key learnings from the STOP-Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1991;4 Suppl 6():1253-5.
1991: Jern S; Hansson L; Scherstén B; Kullman S; Sörensen S; Dahlöf B; Eggertsen R; Sivertsson R
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Journal of cardiovascular pharmacology 1991;18 Suppl 3():S7-8.
1990: Dahlöf B; Gustafsson D; Hedner T; Jern S; Hansson L
Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction.
Journal of hypertension 1990;8(9):811-7.
1990: Dahlöf B
Regression of cardiovascular structural changes--a preventive strategy.
Clinical and experimental hypertension. Part A, Theory and practice 1990;12(5):877-96.
1990: Dahlöf B
Cardiovascular effects of isradipine (Lomir) with special emphasis on haemodynamics and antihypertensive efficacy. A review.
Cor et vasa 1990;32(2 Suppl 1):23-34.
1990: Hansson L; Dahlöf B
Calcium antagonists in the treatment of hypertension: state of the art.
Journal of cardiovascular pharmacology 1990;15 Suppl 4():S71-5.
1989: Dahlöf B
Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension.
The American journal of medicine 1989;86(4A):19-26.
1989: Eggertsen R; Svensson A; Dahlöf B; Hansson L
Additive effect of isradipine in combination with captopril in hypertensive patients.
The American journal of medicine 1989;86(4A):124-6.
1988: Ekbom T; Lindholm L; Odén A; Dahlöf B; Hansson L; Scherstén B; Wester P O
Blood pressure does not predict mortality in the elderly.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(4):S626-8.
1988: Hansson L; Dahlöf B; Gudbrandsson T; Hellsing T; Kullman S; Kuylenstierna J; Leppert J; Möller B; Skogström K; Svensson A
Antihypertensive effect of felodipine or hydralazine when added to beta-blocker therapy.
Journal of cardiovascular pharmacology 1988;12(1):94-101.
1988: Dahlöf B; Hansson L; Acosta J H; Bolzano K; Fairhurst G; Ferreira C; Kaarsalo E; Silva M C; Simone A
Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients.
American journal of hypertension 1988;1(1):38-41.
1988: Dahlöf B; Eggertsen R; Hansson L
Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of hypertension.
Journal of cardiovascular pharmacology 1988;12 Suppl 6():S104-8.
1987: Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Hansson L
The long-term effect of isradipine in pindolol-treated patients.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1987;5(5):S567-70.
1987: Dahlöf B; Hansson L; Lindholm L; Schersten B; Wester P O
STOP-Hypertension--preliminary communication from the pilot study of the Swedish Trial in Old Patients with Hypertension.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1987;5(5):S607-10.
1987: Dahlöf B
The role of antihypertensive pharmacologic treatment in countering adverse pathophysiological profiles: influence on small arteries.
American heart journal 1987;114(4 Pt 2):984-91.
1987: Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Sievert A; Aurell M; Hansson L
Addition of the calcium antagonist PN 200-110 to pindolol markedly augments the antihypertensive effect in essential hypertension.
Journal of cardiovascular pharmacology 1987;10 Suppl 10():S102-4.
1985: Dahlöf B; Andrén L; Eggertsen R; Jern S; Svensson A; Hansson L
Potentiation of the antihypertensive effect of enalapril by randomized addition of different doses of hydrochlorothiazide.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1985;3(3):S483-6.
1983: Andrén L; Dahlöf B; Eggertsen R; Gudbrandsson T; Hansson L; Jern S; Sivertsson R; Svensson A
[A review of recent pharmacological therapeutic principles in hypertension]
Läkartidningen 1983;80(10):945-58.
1983: Andrén L; Dahlöf B; Eggertsen R; Gudbrandsson T; Hansson L; Jern S; Sivertsson R; Svensson A
[Review of new pharmacological treatment principles in hypertension]
Nordisk medicin 1983;98(5):136-41.

Sign-in to see more